Bronchoalveolar lavage fluid analysis provides diagnostic information on pulmonary Langerhans cell histiocytosis

Yuko Takizawa1, Namiko Taniuchi, Mohammad Ghazizadeh

  • 1Department of Molecular Pathology, Graduate School of Medicine, Nippon Medical School, Kawasaki, Kanagawa, Japan.

Insights

Diagnosing pulmonary Langerhans cell histiocytosis (PLCH) can be aided by analyzing Langerhans cells (LCs) in bronchoalveolar lavage fluid (BALF). Increased LC percentages in BALF suggest PLCH, offering a less invasive diagnostic option than lung biopsy.

Area of Science:

  • Pulmonology
  • Pathology
  • Immunocytochemistry

Background:

  • Langerhans cells (LCs) are found in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung diseases.
  • Immunostaining for S-100, CD1a, and langerin identifies LCs.
  • Pulmonary Langerhans cell histiocytosis (PLCH) diagnosis often requires invasive lung biopsy.

Purpose of the Study:

  • To evaluate the diagnostic value of BALF analysis for pulmonary Langerhans cell histiocytosis (PLCH).
  • To compare LC percentages in BALF from PLCH patients versus a control group with other lung diseases.

Main Methods:

  • Retrospective clinicopathological study of 5 patients with biopsy-confirmed PLCH.
  • Analysis of BALF cells from 23 control patients with various lung conditions.
  • Cytospins stained with Giemsa/Papanicolaou and immunocytochemical staining (S-100, CD1a).

Main Results:

  • BALF cytology revealed dispersed histiocytes with characteristic LC morphology.
  • Mean LC percentage in PLCH patients was 8.0% compared to 0.3% in controls.
  • Immunocytochemical results correlated with morphological identification of LCs.

Conclusions:

  • Surveying LCs in BALF, combined with immunocytochemistry and clinical data, is critical for diagnosing PLCH.
  • BALF analysis offers a less invasive diagnostic approach compared to lung biopsy for PLCH.
  • This method can reduce risks associated with invasive procedures.

Related Concept Videos